Nestlé Ponders Least Painful Exit From Peanut Allergy Misfire
Takes $2.1bn Impairment
Heralded as a potential blockbuster, Nestlé's acquisition of Palforzia has proved to be a very expensive mistake.
You may also be interested in...
Moderna and Life Edit will team up to develop transformative or curative therapies for challenging genetic diseases. Erytech and Pherecydes unveil plan to merge and extend runway into 2024.
VMS, active nutrition and medical nutrition will be Nestle Health Science's main focus areas going forward with the business looking to offload peanut allergy treatment Palforzia. The Swiss firm announced the move as it reported organic growth of 4% at Health Science for 2022.
Following regulatory setbacks in the US and also now in the EU, DBV Technologies is to conduct a new pivotal trial of a modified version of its peanut allergy patch to support its efforts to win marketing approval.